Analysis of TNDM Put Selling Strategy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Should l Buy TNDM?
Source: NASDAQ.COM
- Options Selling Risk: Selling puts on TNDM does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, indicating a higher risk in this strategy.
- Exercise Condition Analysis: The contract will only be exercised if TNDM's stock price falls 37.4% to $13, resulting in a cost basis of $11.25 per share, highlighting the impact of market price fluctuations on the options strategy.
- Annualized Yield: The only upside for the put seller comes from the premium collected, with an annualized return of 14.2%, indicating that the seller must bear corresponding risks to achieve this return under current market conditions.
- Volatility Consideration: TNDM's trailing twelve-month volatility is 79%, and investors should carefully assess whether selling puts at the $13 strike price aligns with their risk-return profile when combined with fundamental analysis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNDM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNDM
Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 26.33 USD with a low forecast of 14.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
8 Buy
10 Hold
0 Sell
Moderate Buy
Current: 18.940
Low
14.00
Averages
26.33
High
55.00
Current: 18.940
Low
14.00
Averages
26.33
High
55.00
About TNDM
Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rosen Law Firm Investigates Securities Claims for Tandem Diabetes Care
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) for possibly issuing misleading business information, indicating significant legal risks for the company and potential losses for investors.
- Stock Price Plunge: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, highlighting market concerns over the company's transparency and reliability.
- Class Action Preparation: The firm is preparing a class action lawsuit to seek compensation for affected investors, allowing them to join without any upfront costs, thus providing a viable legal recourse for those impacted by the stock's decline.
- Firm's Track Record: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong capabilities and successful history in handling complex securities litigation.
See More
Rosen Law Firm Investigates Tandem Diabetes for Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ:TNDM) for possibly issuing materially misleading business information, indicating significant legal risks for the company.
- Stock Price Plunge: On August 7, 2025, Tandem Diabetes' stock fell by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, reflecting market concerns over the company's transparency and reliability.
- Class Action Preparation: The firm is preparing a class action lawsuit, allowing investors to seek compensation without any out-of-pocket fees, which may encourage more affected investors to participate and potentially increase the likelihood of successful claims.
- Law Firm Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases effectively.
See More
Rosen Law Firm Investigates Securities Claims for Tandem Diabetes Care
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) for allegedly issuing materially misleading business information, raising serious concerns about the company's transparency and governance.
- Stock Price Impact: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, indicating a significant loss of market confidence in the safety of its products.
- Class Action Preparation: The firm is preparing a class action to seek recovery for investor losses, highlighting the legal risks the company faces, which could adversely affect its future financial performance and market reputation.
- Commitment to Legal Services: Rosen Law Firm offers compensation services without upfront fees, emphasizing its successful track record in securities class actions, which may attract more affected investors to join the lawsuit.
See More
Analysis of TNDM Put Selling Strategy
- Options Selling Risk: Selling puts on TNDM does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, indicating a higher risk in this strategy.
- Exercise Condition Analysis: The contract will only be exercised if TNDM's stock price falls 37.4% to $13, resulting in a cost basis of $11.25 per share, highlighting the impact of market price fluctuations on the options strategy.
- Annualized Yield: The only upside for the put seller comes from the premium collected, with an annualized return of 14.2%, indicating that the seller must bear corresponding risks to achieve this return under current market conditions.
- Volatility Consideration: TNDM's trailing twelve-month volatility is 79%, and investors should carefully assess whether selling puts at the $13 strike price aligns with their risk-return profile when combined with fundamental analysis.
See More
Rosen Law Firm Investigates Tandem Diabetes Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) due to allegations of misleading business information, indicating possible legal liabilities for the company.
- Significant Stock Drop: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, reflecting serious market concerns about the company's transparency.
- Class Action Preparation: The firm is preparing a class action to recover investor losses, with no out-of-pocket fees for participants, which may encourage more affected shareholders to join the lawsuit.
- Firm's Track Record: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases.
See More
Rosen Law Firm Investigates TNDM Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) for possibly issuing materially misleading business information, indicating significant legal risks for the company.
- Stock Price Plunge: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, reflecting market concerns over the company's transparency.
- Class Action Preparation: The firm is preparing a class action lawsuit, allowing investors to seek compensation without any out-of-pocket fees, which may attract more affected investors and increase the likelihood of successful claims.
- Firm's Track Record: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases.
See More
Rosen Law Firm Investigates Securities Claims for Tandem Diabetes Care
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) for possibly issuing misleading business information, indicating significant legal risks for the company and potential losses for investors.
- Stock Price Plunge: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, highlighting market concerns over the company's transparency and reliability.
- Class Action Preparation: The firm is preparing a class action lawsuit to seek compensation for affected investors, allowing them to join without any upfront costs, thus providing a viable legal recourse for those impacted by the stock's decline.
- Firm's Track Record: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong capabilities and successful history in handling complex securities litigation.
See More
Rosen Law Firm Investigates Tandem Diabetes for Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ:TNDM) for possibly issuing materially misleading business information, indicating significant legal risks for the company.
- Stock Price Plunge: On August 7, 2025, Tandem Diabetes' stock fell by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, reflecting market concerns over the company's transparency and reliability.
- Class Action Preparation: The firm is preparing a class action lawsuit, allowing investors to seek compensation without any out-of-pocket fees, which may encourage more affected investors to participate and potentially increase the likelihood of successful claims.
- Law Firm Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases effectively.
See More
Rosen Law Firm Investigates Securities Claims for Tandem Diabetes Care
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) for allegedly issuing materially misleading business information, raising serious concerns about the company's transparency and governance.
- Stock Price Impact: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, indicating a significant loss of market confidence in the safety of its products.
- Class Action Preparation: The firm is preparing a class action to seek recovery for investor losses, highlighting the legal risks the company faces, which could adversely affect its future financial performance and market reputation.
- Commitment to Legal Services: Rosen Law Firm offers compensation services without upfront fees, emphasizing its successful track record in securities class actions, which may attract more affected investors to join the lawsuit.
See More
Analysis of TNDM Put Selling Strategy
- Options Selling Risk: Selling puts on TNDM does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, indicating a higher risk in this strategy.
- Exercise Condition Analysis: The contract will only be exercised if TNDM's stock price falls 37.4% to $13, resulting in a cost basis of $11.25 per share, highlighting the impact of market price fluctuations on the options strategy.
- Annualized Yield: The only upside for the put seller comes from the premium collected, with an annualized return of 14.2%, indicating that the seller must bear corresponding risks to achieve this return under current market conditions.
- Volatility Consideration: TNDM's trailing twelve-month volatility is 79%, and investors should carefully assess whether selling puts at the $13 strike price aligns with their risk-return profile when combined with fundamental analysis.
See More
Rosen Law Firm Investigates Tandem Diabetes Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) due to allegations of misleading business information, indicating possible legal liabilities for the company.
- Significant Stock Drop: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, reflecting serious market concerns about the company's transparency.
- Class Action Preparation: The firm is preparing a class action to recover investor losses, with no out-of-pocket fees for participants, which may encourage more affected shareholders to join the lawsuit.
- Firm's Track Record: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases.
See More
Rosen Law Firm Investigates TNDM Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) for possibly issuing materially misleading business information, indicating significant legal risks for the company.
- Stock Price Plunge: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, reflecting market concerns over the company's transparency.
- Class Action Preparation: The firm is preparing a class action lawsuit, allowing investors to seek compensation without any out-of-pocket fees, which may attract more affected investors and increase the likelihood of successful claims.
- Firm's Track Record: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases.
See More
